US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

Marc Perez, a Bayside local, is in need of a lifesaving kidney transplant from a living donor after being diagnosed with a ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

COVID-19 testing includes molecular (PCR), antigen (rapid), and antibody (serology) tests, each serving different ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq ...

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) today announced the US Food and Drug Administration (FDA) has accepted ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Symptoms manifest themselves in the kidney, as function progressively deteriorates as the organ becomes inflamed as a result of lodged IgA antibody complexes. These IgA antibodies are actually ...

After four years of heartbreak and a promise to his sister, Junction’s Aidan Cardwell looked to the sky—then finally stood atop the podium in Austin.

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...